Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Travis D Fischer
Observed names:
Fischer, Travis David,
Travis D. Fischer,
Travis Fischer
Institutions:
University of Iowa,
University of Iowa Health Care,
University of Iowa Holden Comprehensive Cancer Center
Observed institutions:
University of Iowa,
University of Iowa Health Care,
University of Iowa Holden Comprehensive Cancer Center
ORCID:
0000-0002-6751-7149
Observed ORCID:
0000-0002-6751-7149
OpenAlex ID:
A5111084723
BDCA2 plays a central role in the binding, internalization and response of plasmacytoid dendritic cells to vidutolimod
2026
·
Caitlin D. Lemke-Miltner
, Sue E. Blackwell
, et al.
·
Frontiers in Immunology
·
2
PDF
Data from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
·
1
Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
·
Cancer Research Communications
·
1
Supplementary Figure S7 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 3 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S2 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S6 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 4 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 6 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S1 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S5 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 1 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S4 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 7 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 5 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Supplementary Figure S3 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Figure 2 from Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells
2026
·
Travis D. Fischer
, Caitlin D. Lemke-Miltner
, et al.
Virus-like particles containing a TLR9 agonist enhance the anti-tumor T cell response
2026
·
Fischer, Travis David
·
Iowa Research Online (The University of Iowa)
PDF
917 Treatment with virus-like particles containing a TLR9-agonist enhances and extends the activation of tumor-specific CD8+ T cells
2025
·
Travis D Fischer
, Caitlin D Lemke-Miltner
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1027 Intratumoral injection of vidutolimod, an immunostimulatory virus-like particle, enhances the number of intratumoral and circulating tumor-specific CD8 T cells
2024
·
Travis D Fischer
, Caitlin D Lemke-Miltner
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract B002: Vidutolimod, an immunostimulatory virus-like particle, reduces proliferation but enhances the activation of tumor-specific T cells
2023
·
Travis D. Fischer
, Caitlin Lemke-Miltner
, et al.
·
Cancer Immunology Research
1122 Vidutolimod, an immunostimulatory virus-like particle, reduces proliferation but enhances the activation of tumor-specific T cells
2023
·
Travis D Fischer
, Caitlin D Lemke-Miltner
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 2804: Generation of RNA aptamers for measuring fractional occupancy of PD1 by PDL1
2022
·
Suresh Veeramani
, Travis Fischer
, et al.
·
Cancer Research
Show more works
View as search
Works count:
23
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type